Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PaperCitations, authors & open-access status
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 262 citations, 2019 year and closed oa status.
262
Citations
2019
Year
closed
OA Status